세계의 의약품 첨가제 시장 : 예측(2024-2029년)

The global pharmaceutical excipients market is projected to witness a CAGR of 9.23% during the forecast period to reach a total market size of US$12.822 billion by 2029, increasing from US$6.917 billion in 2022.

Excipients are pharmacologically dormant substances included in conjunction with the dynamic medicate substance to streamline the production of the drug item and help in lubricity, flowability, deterioration, and taste. They may bestow a few shapes of antimicrobial work and additionally encourage the physiological assimilation of the sedate. A few of the excipients utilized in pharmaceutical industries include fillers, binders, oils, flavoring specialists, sweeteners, chelating operators, solvents, co-solvents, etc. To supply the bulk dose formulations steady in physical and chemical, the formulator is profoundly subordinate to the pharmaceutical excipients.

A few pharmaceutical dosage forms that are easily and widely available and utilized globally are tablets, capsules, topical creams and gels, implants, oral dosage, eye drops, injectable products, inhalers, transdermal patches, lozenges, and suppositories. Pharmaceutical excipients are utilized in these pharmaceutical medication formulations to help the processing, providing bulk or volume to API, and securing, supporting, or incrementing the stability of the dosage forms in the final product.

Cancer, acute respiratory disease, heart stroke, diabetes, and other chronic diseases are the major driving factors of rising mortality in the world. Inside the United States alone, six out of ten individuals endure chronic illness regularly and require persistent and regular pharmaceutical medicines regime intake. As per the International Diabetes Federation (IDF), around 463 million people (20-79 years adults) were living with diabetes in 2019, and by 2045, the number is expected to increase to 700 million, showing a rise in demand for medicines in turn boosting the Pharmaceutical Excipients market growth.

Market Drivers:

• Increasing research and development (R&D) is expected to boost the pharmaceutical excipients market.

Expanded investigations and advancements in pharmaceutical formulations utilize multi-functional excipients to progress the process of production and medication quality. Excipients play a significant part in helping pharmaceutical manufacturers in giving progress persistent bolster by improving compliance and treatment viability.

The pharmaceutical industry's rising attention on R&D is anticipated to emphatically affect the industry for pharmaceutical excipients. These inert substances improve medicate steadiness and solvency and help in medicate delivery forms. They play a vital part in medication advancement, influencing the bioavailability, discharge profile, and solidness of dynamic drugs. R&D endeavors drive advancement in pharmaceutical medication details, with progressed sedate conveyance frameworks such as nanoparticles and liposomes frequently requiring specialized excipients.

Administrative bodies just like the FDA and EMA continuously upgrade regulations standard guidelines and benchmarks for pharmaceutical items, driving the requirement for excipients that meet the most recent measures. Customization of medication formulations on the basis of particular patient needs and restorative zones are significant. As pharmaceutical companies contribute to R&D all-inclusive, the request for pharmaceutical excipients is likely to extend around the world, with producers seeing expanded openings to supply to broader regions in the years ahead.

• A rise in chronic diseases is expected to surge the pharmaceutical excipients market growth.

The rising generics medicine industry is driven by the rise in chronic illnesses and the improvement of excipients, which are a key figure within the pharmaceutical market growth. The rise in major chronic disorders, like cardiovascular, diabetes, cancer, and chronic respiratory conditions, is fueling the demand for different treatment alternatives.

Pharmaceutical companies are creating innovative medication formulations for fulfilling the requirement as well as emerging delivery frameworks to progress adequacy and effectiveness with the comfort and compliance of patients. These medicines frequently include complex regimens, requiring pharmaceutical excipients to improve the stability of the medicine, control release rates of the drug, and enhance its bioavailability. Specialized drug delivery systems are necessary for sustained release, targeted delivery to specific tissues, and overcoming solubility and absorption issues.

Pharmaceutical excipients can also be used to create patient-friendly dosage forms, such as extended-release tablets or convenient oral formulations. Innovations in therapeutic approaches, such as personalized medicine and biologics, often require specialized excipients for stability and effectiveness. Government initiatives and healthcare policies aimed at improving access to effective treatments for chronic diseases may contribute to the pharmaceutical excipient market growth.

Market Restraints:

• Cost and time consumed in creating new excipients could hinder the market growth.

Pharmaceutical Excipients require mandatory inspections by the regulatory authorities of the manufacturing site. The industry lacks separate guidelines for approval and manufacturing of excipients is impending R&D initiatives related to excipients. If a new drug approval fails, the excipient also fails, even if it is not related to the excipient. Moreover, a considerable amount of time and cost goes into creating an excipient.

Key Developments:

• October 2023- Lubrizol Life Science Health won the Finished Formulation Award at CPhI Barcelona for its innovative technology, Apisolex(TM) Polymer solubilizing excipient. The award, which was recognized by The Medicine Maker, was awarded to a breakthrough innovation among over 180 entries in 12 innovation categories. The winners were announced at a networking reception with over 500 attendees.Apisolex(TM) Polymer, a poly(amino acid)-based excipient, is the first solubility-enhancing excipient for parenteral use in over 20 years, enhancing hydrophobic API solubility by up to 50,000-fold.
• October 2023- Clariant Health Care launched a new range of excipients at CPHI Barcelona to improve the stability and solubility of active pharmaceutical ingredient (API) formulations. The company will unveil three new VitiPure(R) excipients, which can be used for various API formulations and administration routes, including sensitive ones like mRNA vaccines and biological medications. Clariant Health Care is a one-stop shop solution provider of excipients, offering a range from standard to highly purified grades for unique application-specific formulation flexibility.
• October 2023- Roquette added three new excipient grades for moisture-sensitive active pharmaceutical and nutraceutical ingredients to its portfolio. These grades, including partially pregelatinized starch Lycatab CT-LM, Microcel 103 SD, and Microcel 113 SD, are microcrystalline cellulose with unique stabilizing and moisture-protective benefits. These ingredients are designed to help pharmaceutical manufacturers optimize drug delivery, regardless of production method or formulation type. Roquette's moisture protection profile incorporated a comprehensive variety of low water activity (Aw) excipients, which bolster effective drug advancement in applications including moisture-sensitive active ingredients.
• July 2022- DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions, expanded its Dry Powder Inhalation (DPI) portfolio with the launch of Lactohale(R) 400. This new grade can be customized to meet specific pharmaceutical company needs and developed jointly with formulators to ensure the right outcomes for patients. DFE Pharma's comprehensive range of lactose-based excipients is designed to offer the right characteristics for the full variety of inhaled medicines in the market. Lactohale(R) 400 is a milled, anhydrous lactose grade suitable for DPI applications requiring good flow and cohesiveness.

Key Segmentation:

Global Pharmaceutical Excipients Market is segmented and analyzed as below:

By Excipient Type

• Polymers
• Alcohols
• Sugars
• Minerals
• Others

By Formulation Type

• Oral
• Topical
• Parenteral
• Others

By Functionality

• Coating Agents
• Flavoring Agents & Sweeteners
• Lubricants & Glidants
• Colorants
• Emulsifying Agents
• Buffering Agents
• Others

By Distribution Channel

• Online
• Offline

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• Australia
• Japan
• South Korea
• India
• Thailand
• Taiwan
• Indonesia
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base and Forecast Years Timeline
• 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

• 2.1. Research Design
• 2.2. Research Processes

3. EXECUTIVE SUMMARY

• 3.1. Key Findings

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis
• 4.5. Analyst View

5. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT TYPE

• 5.1. Introduction
• 5.2. Polymers
  • 5.2.1. Market Opportunities and Trends
  • 5.2.2. Growth Prospects
  • 5.2.3. Geographic Lucrativeness
• 5.3. Alcohols
  • 5.3.1. Market Opportunities and Trends
  • 5.3.2. Growth Prospects
  • 5.3.3. Geographic Lucrativeness
• 5.4. Sugars
  • 5.4.1. Market Opportunities and Trends
  • 5.4.2. Growth Prospects
  • 5.4.3. Geographic Lucrativeness
• 5.5. Minerals
  • 5.5.1. Market Opportunities and Trends
  • 5.5.2. Growth Prospects
  • 5.5.3. Geographic Lucrativeness
• 5.6. Others
  • 5.6.1. Market Opportunities and Trends
  • 5.6.2. Growth Prospects
  • 5.6.3. Geographic Lucrativeness

6. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET BY FORMULATION TYPE

• 6.1. Introduction
• 6.2. Oral
  • 6.2.1. Market Opportunities and Trends
  • 6.2.2. Growth Prospects
  • 6.2.3. Geographic Lucrativeness
• 6.3. Topical
  • 6.3.1. Market Opportunities and Trends
  • 6.3.2. Growth Prospects
  • 6.3.3. Geographic Lucrativeness
• 6.4. Parenteral
  • 6.4.1. Market Opportunities and Trends
  • 6.4.2. Growth Prospects
  • 6.4.3. Geographic Lucrativeness
• 6.5. Others
  • 6.5.1. Market Opportunities and Trends
  • 6.5.2. Growth Prospects
  • 6.5.3. Geographic Lucrativeness

7. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET BY FUNCTIONALITY

• 7.1. Introduction
• 7.2. Coating Agents
  • 7.2.1. Market Opportunities and Trends
  • 7.2.2. Growth Prospects
  • 7.2.3. Geographic Lucrativeness
• 7.3. Flavoring Agents & Sweeteners
  • 7.3.1. Market Opportunities and Trends
  • 7.3.2. Growth Prospects
  • 7.3.3. Geographic Lucrativeness
• 7.4. Lubricants & Glidants
  • 7.4.1. Market Opportunities and Trends
  • 7.4.2. Growth Prospects
  • 7.4.3. Geographic Lucrativeness
• 7.5. Colorants
  • 7.5.1. Market Opportunities and Trends
  • 7.5.2. Growth Prospects
  • 7.5.3. Geographic Lucrativeness
• 7.6. Emulsifying Agents
  • 7.6.1. Market Opportunities and Trends
  • 7.6.2. Growth Prospects
  • 7.6.3. Geographic Lucrativeness
• 7.7. Buffering Agents
  • 7.7.1. Market Opportunities and Trends
  • 7.7.2. Growth Prospects
  • 7.7.3. Geographic Lucrativeness
• 7.8. Others
  • 7.8.1. Market Opportunities and Trends
  • 7.8.2. Growth Prospects
  • 7.8.3. Geographic Lucrativeness

8. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET BY DISTRIBUTION CHANNEL

• 8.1. Introduction
• 8.2. Online
  • 8.2.1. Market Opportunities and Trends
  • 8.2.2. Growth Prospects
  • 8.2.3. Geographic Lucrativeness
• 8.3. Offline
  • 8.3.1. Market Opportunities and Trends
  • 8.3.2. Growth Prospects
  • 8.3.3. Geographic Lucrativeness

9. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. By Excipient Type
  • 9.2.2. By Formulation Type
  • 9.2.3. By Functionality
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
    • 9.2.5.1. USA
      • 9.2.5.1.1. Market Opportunities and Trends
      • 9.2.5.1.2. Growth Prospects
    • 9.2.5.2. Canada
      • 9.2.5.2.1. Market Opportunities and Trends
      • 9.2.5.2.2. Growth Prospects
    • 9.2.5.3. Mexico
      • 9.2.5.3.1. Market Opportunities and Trends
      • 9.2.5.3.2. Growth Prospects
• 9.3. South America
  • 9.3.1. By Excipient Type
  • 9.3.2. By Formulation Type
  • 9.3.3. By Functionality
  • 9.3.4. By Distribution Channel
  • 9.3.5. By Country
    • 9.3.5.1. Brazil
      • 9.3.5.1.1. Market Opportunities and Trends
      • 9.3.5.1.2. Growth Prospects
    • 9.3.5.2. Argentina
      • 9.3.5.2.1. Market Opportunities and Trends
      • 9.3.5.2.2. Growth Prospects
    • 9.3.5.3. Others
      • 9.3.5.3.1. Market Opportunities and Trends
      • 9.3.5.3.2. Growth Prospects
• 9.4. Europe
  • 9.4.1. By Excipient Type
  • 9.4.2. By Formulation Type
  • 9.4.3. By Functionality
  • 9.4.4. By Distribution Channel
  • 9.4.5. By Country
    • 9.4.5.1. Germany
      • 9.4.5.1.1. Market Opportunities and Trends
      • 9.4.5.1.2. Growth Prospects
    • 9.4.5.2. France
      • 9.4.5.2.1. Market Opportunities and Trends
      • 9.4.5.2.2. Growth Prospects
    • 9.4.5.3. UK
      • 9.4.5.3.1. Market Opportunities and Trends
      • 9.4.5.3.2. Growth Prospects
    • 9.4.5.4. Italy
      • 9.4.5.4.1. Market Opportunities and Trends
      • 9.4.5.4.2. Growth Prospects
    • 9.4.5.5. Spain
      • 9.4.5.5.1. Market Opportunities and Trends
      • 9.4.5.5.2. Growth Prospects
    • 9.4.5.6. Others
      • 9.4.5.6.1. Market Opportunities and Trends
      • 9.4.5.6.2. Growth Prospects
• 9.5. Middle East and Africa
  • 9.5.1. By Excipient Type
  • 9.5.2. By Formulation Type
  • 9.5.3. By Functionality
  • 9.5.4. By Distribution Channel
  • 9.5.5. By Country
    • 9.5.5.1. Saudi Arabia
      • 9.5.5.1.1. Market Opportunities and Trends
      • 9.5.5.1.2. Growth Prospects
    • 9.5.5.2. UAE
      • 9.5.5.2.1. Market Opportunities and Trends
      • 9.5.5.2.2. Growth Prospects
    • 9.5.5.3. Israel
      • 9.5.5.3.1. Market Opportunities and Trends
      • 9.5.5.3.2. Growth Prospects
    • 9.5.5.4. Others
      • 9.5.5.4.1. Market Opportunities and Trends
      • 9.5.5.4.2. Growth Prospects
• 9.6. Asia Pacific
  • 9.6.1. By Excipient Type
  • 9.6.2. By Formulation Type
  • 9.6.3. By Functionality
  • 9.6.4. By Distribution Channel
  • 9.6.5. By Country
    • 9.6.5.1. China
      • 9.6.5.1.1. Market Opportunities and Trends
      • 9.6.5.1.2. Growth Prospects
    • 9.6.5.2. Australia
      • 9.6.5.2.1. Market Opportunities and Trends
      • 9.6.5.2.2. Growth Prospects
    • 9.6.5.3. Japan
      • 9.6.5.3.1. Market Opportunities and Trends
      • 9.6.5.3.2. Growth Prospects
    • 9.6.5.4. South Korea
      • 9.6.5.4.1. Market Opportunities and Trends
      • 9.6.5.4.2. Growth Prospects
    • 9.6.5.5. India
      • 9.6.5.5.1. Market Opportunities and Trends
      • 9.6.5.5.2. Growth Prospects
    • 9.6.5.6. Thailand
      • 9.6.5.6.1. Market Opportunities and Trends
      • 9.6.5.6.2. Growth Prospects
    • 9.6.5.7. Taiwan
      • 9.6.5.7.1. Market Opportunities and Trends
      • 9.6.5.7.2. Growth Prospects
    • 9.6.5.8. Indonesia
      • 9.6.5.8.1. Market Opportunities and Trends
      • 9.6.5.8.2. Growth Prospects
    • 9.6.5.9. Others
      • 9.6.5.9.1. Market Opportunities and Trends
      • 9.6.5.9.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. Ashland Global Holdings
• 11.2. DuPont
• 11.3. BASF SE
• 11.4. Roquette Feres
• 11.5. Evonik Industries AG
• 11.6. Croda International
• 11.7. Associated British Foods
• 11.8. Archer Daniels Midland Company
• 11.9. Lubrizol Corporation